ArticleBritish journal of cancer2014
Estimating breast cancer mortality reduction and overdiagnosis due to screening for different strategies in the United Kingdom.
Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC).British journal of cancer · 2022Pooled it
- Is mammography screening beneficial: An individual-based stochastic model for breast cancer incidence and mortality.PLoS computational biology · 2020Trial
- Trial
- Women's experiences of age-related discontinuation from mammography screening: A qualitative interview study.Health expectations : an international journal of public participation in health care and health policy · 2023Article
- Tumour Growth Models of Breast Cancer for Evaluating Early Detection-A Summary and a Simulation Study.Cancers · 2023Article
- A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis.Production and operations management · 2022Article
- Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort.Annals of internal medicine · 2022Article
- Very poor practices regarding breast cancer screening among Sudanese female workers at a secondary-level hospital: a cross-sectional study.The Pan African medical journal · 2022Article
- Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women.Journal of the National Cancer Institute · 2021Article
- A Panel of Tumor-associated Autoantibodies for the Detection of Early-stage Breast Cancer.Journal of Cancer · 2021Article
- Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin EOncotarget · 2017Article
- Overdiagnosis across medical disciplines: a scoping review.BMJ open · 2017Article
- Targeted Cancer Screening in Average-Risk Individuals.American journal of preventive medicine · 2015Review
- Evaluation of health benefits and harms of the breast cancer screening programme in the Basque Country using discrete event simulation.BMC cancer · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe benefits and harms of population-wide mammography screening have been long debated. This study evaluated the impact of screening frequency and age range on breast cancer mortality reduction and overdiagnosis.
methodsWe developed a Markov simulation model for the evaluation of mammography screening in a cohort of British women born in 1935-40.
resultsFor triennial screening in women aged 47-73, breast cancer mortality reduction and overdiagnosis was 18.1% (95% confidence interval: 17.3%, 19.0%) and 5.6% (5.1%, 6.1%), of all breast cancer deaths and diagnoses, respectively, from age 40 to 85 years. For annual screening in the same age range, estimates for both outcomes increased considerably to 35.0% (34.2%, 35.7%) and 7.6% (7.1%, 8.1%), respectively. For the age extension of triennial screening from 50-70 to 47-73, we estimated 5 (3, 7) incremental breast cancer deaths avoided and 14 (9, 19) incremental cases overdiagnosed per 10 000 women invited for screening.
conclusionsEstimates of mortality reduction and overdiagnosis were highly dependent on screening frequency, age range, and uptake, which may explain differences between some previous estimates obtained from randomised trials and from service screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.